Healthy volunteers help test new Long-Acting HIV drug

NCT ID NCT05418868

First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 15 times

Summary

This early-stage study is testing a long-acting HIV drug called cabotegravir in 214 healthy adults. The goal is to see how the drug moves through the body and if it is safe when given as a shot. Participants do not have HIV and will not receive any direct treatment benefit, but the results will help develop better HIV prevention options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • GSK Investigational Site

    COMPLETED

    Orlando, Florida, 32806, United States

  • GSK Investigational Site

    RECRUITING

    Las Vegas, Nevada, 89113, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • GSK Investigational Site

    RECRUITING

    Austin, Texas, 78744, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.